Replies to post #19820 on Medicine Man Technologies Inc (SHWZ)

[Drugdoctor]

I'm no supporter of Brochstein, but find the sequential decrease in revenue concerning, especially with the acquisitions that continued into the quarter. We can try to ignore saturation of the markets all we want, but it is real and the lack of license controls has caused many operators to pull out of markets, and Schwazze has now shown that despite being a good operator, they are not immune to the over saturation. The closing of the legacy businesses caught me by surprise, but if you are going to report losses anyway, why not get the write offs done in a loser year anyway? The lack of any concern about the 13% interest rate payments and the preferred dividends is also problematic. Seems they are gambling that interest rates may fall before the notes come due. So spend the money wisely, as the well may be running dry...